4D Pharma PLC (DDDD) 2014年年度报告「LSE」.pdf

1、 4D pharma plc(formerly Schosween 18 Limited)Annual Report and Financial StatementsPeriod 10 January 2014 to 31 December 2014Registered No.08840579236661 4D pp001-pp019 05/06/2015 00:34 Page 12Company Information 3Chairman s and Chief Executive Officer s Joint Review 4The Board 6Strategic Report 7Di

2、rectors Report 9Corporate Governance Statement 13Report of the Remuneration Committee 16Independent Auditor s Report 18Group Statement of Comprehensive Income 20Group Statement of Changes in Equity 21Company Statement of Changes in Equity 22Group Statement of Financial Position 23Company Statement o

3、f Financial Position 24Group Cash Flow Statement 25Company Cash Flow Statement 26Notes to the Financial Statements 27Notice of Annual General Meeting 514D pharma plcCONTENTS236661 4D pp001-pp019 05/06/2015 00:35 Page 23Directors David Norwood (Non-executive Chairman)Duncan Peyton (Chief Executive Of

4、ficer)Dr Alexander Stevenson (Chief Scientific Officer)Thomas Engelen (Non-executive Director)Secretary Laurence DaleNominated Advisor and Broker Zeus Capital Limited82 King StreetManchester M2 4WQ and 23 Berkley SquareLondon W1 6HEAuditor Baker Tilly UK Audit LLP 3 Hardman Street Manchester M3 3HFR

5、egistrar Capita Registrars Limited The Registry 34 Beckenham Road Beckenham Kent BR3 4TURegistered Office 74 Gartside Street Manchester M3 3ELWebsite 4D pharma plcCOMPANY INFORMATION236661 4D pp001-pp019 05/06/2015 00:35 Page 344D pharma plc(“4D”,the“Company”and,together with its subsidiaries,the“Gr

6、oup”)is focussed on bringing tomarket a new class of therapeutics known as live biotherapeutics.Rather than chemical entities or antibodies,4Duses carefully selected bacteria as the active ingredients in its products.4D only uses bacteria that have a precise and evolved mechanism of action.As these